ALKS Alkermes plc

Price (delayed)

$28.02

Market cap

$4.61B

P/E Ratio

16.2

Dividend/share

N/A

EPS

$1.73

Enterprise value

$4.45B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
The debt has contracted by 6% YoY
ALKS's quick ratio is up by 4.3% since the previous quarter
The EPS has soared by 184% year-on-year but it has declined by 34% since the previous quarter
Alkermes's net income has soared by 180% YoY but it has decreased by 34% from the previous quarter
Alkermes's gross profit has decreased by 15% from the previous quarter
ALKS's P/E is 4.2% above its last 4 quarters average of 14.7

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
164.67M
Market cap
$4.61B
Enterprise value
$4.45B
Valuations
Price to book (P/B)
3.69
Price to sales (P/S)
3.13
EV/EBIT
17.9
EV/EBITDA
14.81
EV/Sales
2.95
Earnings
Revenue
$1.51B
EBIT
$248.42M
EBITDA
$300.34M
Free cash flow
$425.87M
Per share
EPS
$1.73
Free cash flow per share
$2.53
Book value per share
$7.59
Revenue per share
$8.96
TBVPS
$12.61
Balance sheet
Total assets
$2.21B
Total liabilities
$922.84M
Debt
$368M
Equity
$1.28B
Working capital
$1.03B
Liquidity
Debt to equity
0.29
Current ratio
2.99
Quick ratio
2.41
Net debt/EBITDA
-0.56
Margins
EBITDA margin
19.9%
Gross margin
83.3%
Net margin
19.1%
Operating margin
24.9%
Efficiency
Return on assets
13.2%
Return on equity
22.7%
Return on invested capital
17.1%
Return on capital employed
14.7%
Return on sales
16.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
5.7%
1 week
13.67%
1 month
15.88%
1 year
-9.14%
YTD
1.01%
QTD
16.27%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.51B
Gross profit
$1.26B
Operating income
$375.62M
Net income
$288.72M
Gross margin
83.3%
Net margin
19.1%
Alkermes's net income has soared by 180% YoY but it has decreased by 34% from the previous quarter
The net margin has soared by 173% YoY but it has contracted by 24% from the previous quarter
Alkermes's operating income has decreased by 31% from the previous quarter but it has increased by 15% YoY
The company's operating margin fell by 21% QoQ but it rose by 12% YoY

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
P/E
16.2
P/B
3.69
P/S
3.13
EV/EBIT
17.9
EV/EBITDA
14.81
EV/Sales
2.95
The EPS has soared by 184% year-on-year but it has declined by 34% since the previous quarter
ALKS's P/E is 4.2% above its last 4 quarters average of 14.7
The company's equity rose by 2.3% QoQ
The revenue has contracted by 13% from the previous quarter but it has grown by 3.1% YoY
ALKS's P/S is 8% below its 5-year quarterly average of 3.2 but 6% above its last 4 quarters average of 2.8

Efficiency

How efficient is Alkermes business performance
The ROA has soared by 159% YoY but it fell by 34% QoQ
The return on equity has surged by 141% year-on-year but it has declined by 33% since the previous quarter
The ROS has soared by 72% year-on-year but it has declined by 24% since the previous quarter
The ROIC has soared by 71% YoY but it has decreased by 35% from the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 139% higher than its total liabilities
The current ratio has contracted by 7% from the previous quarter but it has grown by 4.2% YoY
The company's total liabilities rose by 6% QoQ
The debt is 71% less than the equity
The debt has contracted by 6% YoY
The debt to equity is down by 3.3% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.